Background: We conducted a retrospective cohort study to evaluate and compare the longitudinal effect of monotherapy with L-, L/T-, L/N-, and L/N/T-type calcium channel blockers (CCBs) on estimated glomerular filtration rate (eGFR), and to investigate the association of treatment duration with eGFR in diabetic patients with hypertension.
Methods: Using data from the Clinical Data Warehouse of Nihon University School of Medicine, we identified new users of five CCBs with concomitant mild to moderate hypertension and diabetes mellitus (DM). We used a multivariable regression model to evaluate and compare the effects of the drugs on eGFR, up to 12 months after the initiation of study drug administration.
Results: There was no significant association between eGFR and treatment duration in all CCB types. There was no significant difference in mean change in eGFR among the five CCBs with any treatment duration. The mean percentage change of eGFR in L-type CCBs tended to increase during the 0-3 month period. However, there was no significant difference among treatment durations in the five CCB groups.
Conclusions: Our findings suggest that monotherapy with an L-, L/T-, L/N/T-, or L/N-type CCB may have little influence on glomerular function and may be safely used in hypertensive patients with DM, at least up to 12 months.